3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Resectable Pancreatic Cancer
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Adenocarcinoma
1
Interventions
Gemcitabine
57
130-nm albumin-bound paclitaxel
35
Specimen Handling
26
Magnetic Resonance Spectroscopy
21
Albumin-Bound Paclitaxel
21
Fluorouracil
20
Leucovorin
19
Irinotecan
19
Oxaliplatin
17
Biopsy
17
Taxes
16
pembrolizumab
14
Cyclophosphamide
12
Cisplatin
11
fludarabine
10
Cetuximab
9
Capecitabine
8
Radiosurgery
7
Nivolumab
7
Carboplatin
7
irinotecan sucrosofate
6
durvalumab
6
dehydroftorafur
6
Pemetrexed
6
olaparib
5
Ipilimumab
5
Erlotinib Hydrochloride
5
trastuzumab deruxtecan
4
aldesleukin
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
paricalcitol
×
90 days
×
Clear all
NCT03415854
2026-05-12
NABPLAGEMD
HonorHealth Research Institute
Phase 2
Completed
34 enrolled
11 charts